L E Charvet1, E H O'Donnell2, A L Belman1, T Chitnis2, J M Ness3, J Parrish4, M Patterson5, M Rodriguez5, E Waubant6, B Weinstock-Guttman4, L B Krupp7. 1. Lourie Center for Pediatric Multiple Sclerosis (MS), Stony Brook Medicine, USA. 2. Partners Pediatric MS Center, Massachusetts General Hospital for Children, USA. 3. Center for Pediatric-Onset Demyelinating Disease, Children's Hospital of Alabama, University of Alabama at Birmingham USA. 4. Pediatric MS Center, University at Buffalo, USA. 5. Pediatric MS Center, Mayo Clinic, USA. 6. Regional Pediatric MS Center, University of California at San Francisco, USA. 7. Stony Brook Medicine Lourie Center for Pediatric MS, Department of Neurology, Stony Brook, NY, USA lauren.krupp@stonybrookmedicine.edu.
Abstract
BACKGROUND: Approximately one-third of those with pediatric-onset multiple sclerosis (MS) experience cognitive impairment. Less is known concerning their change in cognitive functioning over time. OBJECTIVE: Changes in cognitive function over time were measured in the largest pediatric cohort to date through the US Network of Pediatric MS Centers. METHODS: A total of 67 individuals with pediatric MS (n=62) or clinically isolated syndrome (CIS, n=5), ranging from 8-17 years of age (mean age ± standard deviation (SD)=14.37 ± 2.02) completed initial and follow-up neuropsychological testing after an average of 1.64 ± 0.63 years apart. The nine tests administered measure general intellect, attention and working memory, verbal memory, visuomotor integration, language, and executive functioning. RESULTS: Rate of impairment (having one-third or more scores in the impaired range) was 37% at baseline and 33% at follow-up. Tests commonly impaired were measures of visuomotor integration, speeded processing, and attention. Most tested did not decline over two years. There was no clear pattern of change on any specific measure. CONCLUSION: Findings suggest that, over short timeframes, stable or even improved performances on measures of cognitive ability can occur. Pediatric MS may instead prevent expected age-related cognitive gains.
BACKGROUND: Approximately one-third of those with pediatric-onset multiple sclerosis (MS) experience cognitive impairment. Less is known concerning their change in cognitive functioning over time. OBJECTIVE: Changes in cognitive function over time were measured in the largest pediatric cohort to date through the US Network of Pediatric MS Centers. METHODS: A total of 67 individuals with pediatric MS (n=62) or clinically isolated syndrome (CIS, n=5), ranging from 8-17 years of age (mean age ± standard deviation (SD)=14.37 ± 2.02) completed initial and follow-up neuropsychological testing after an average of 1.64 ± 0.63 years apart. The nine tests administered measure general intellect, attention and working memory, verbal memory, visuomotor integration, language, and executive functioning. RESULTS: Rate of impairment (having one-third or more scores in the impaired range) was 37% at baseline and 33% at follow-up. Tests commonly impaired were measures of visuomotor integration, speeded processing, and attention. Most tested did not decline over two years. There was no clear pattern of change on any specific measure. CONCLUSION: Findings suggest that, over short timeframes, stable or even improved performances on measures of cognitive ability can occur. Pediatric MS may instead prevent expected age-related cognitive gains.
Authors: M P Amato; B Goretti; A Ghezzi; S Lori; V Zipoli; L Moiola; M Falautano; M F De Caro; R Viterbo; F Patti; R Vecchio; C Pozzilli; V Bianchi; M Roscio; V Martinelli; G Comi; E Portaccio; M Trojano Journal: Neurology Date: 2010-09-28 Impact factor: 9.910
Authors: J S Fischer; R L Priore; L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; D E Goodkin; C V Granger; J H Simon; J H Grafman; M D Lezak; K M O'Reilly Hovey; K K Perkins; D Barilla-Clark; M Schacter; D W Shucard; A L Davidson; K E Wende; D N Bourdette; M F Kooijmans-Coutinho Journal: Ann Neurol Date: 2000-12 Impact factor: 10.422
Authors: A M Smerbeck; J Parrish; E A Yeh; M Hoogs; Lauren B Krupp; B Weinstock-Guttman; R H B Benedict Journal: Clin Neuropsychol Date: 2011-03-07 Impact factor: 3.535
Authors: A M Smerbeck; J Parrish; E A Yeh; B Weinstock-Guttman; M Hoogs; D Serafin; L Krupp; R H B Benedict Journal: Clin Neuropsychol Date: 2012 Impact factor: 3.535
Authors: Laura Julian; Dana Serafin; Leigh Charvet; Joseph Ackerson; Ralph Benedict; Ellen Braaten; Tanya Brown; Ellen O'Donnell; Joy Parrish; Thomas Preston; Michael Zaccariello; Anita Belman; Tanuja Chitnis; Mark Gorman; Jayne Ness; Marc Patterson; Moses Rodriguez; Emmanuelle Waubant; Bianca Weinstock-Guttman; Ann Yeh; Lauren B Krupp Journal: J Child Neurol Date: 2012-11-15 Impact factor: 1.987
Authors: Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst-Wilhelm Radü; Carola Metzig; Lars Bauer; Vivian Lanius; Rupert Sandbrink; Christoph Pohl Journal: Lancet Neurol Date: 2009-09-10 Impact factor: 44.182
Authors: Jonathan D Santoro; Michael Waltz; Greg Aaen; Anita Belman; Leslie Benson; Mark Gorman; Manu S Goyal; Jennifer S Graves; Yolanda Harris; Lauren Krupp; Timothy Lotze; Soe Mar; Manikum Moodley; Jayne Ness; Mary Rensel; Moses Rodriguez; Teri Schreiner; Jan-Mendelt Tillema; Emmanuelle Waubant; Bianca Weinstock-Guttman; Brigitte F Hurtubise; Shelly Roalstad; John Rose; T Charles Casper; Tanuja Chitnis Journal: Neurology Date: 2020-07-20 Impact factor: 9.910